Mylan and Biocon launch first Trastuzumab Biosimilar, Ogivri, in Australia EP News Bureau Aug 1, 2019 Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme…
Biocon Q1FY20 Revenue grows by 25 per cent EP News Bureau Jul 26, 2019 EBITDA up 51 per cent at Rs 462 crores, net profit (excluding exceptional item) up 86 per cent at Rs 223 crores, small molecules…
